Although the Department of Justice (DOJ) announced on Oct. 30 that it had settled with 457 hospitals for allegedly improperly implanting implantable cardioverter defibrillators (ICDs), it said it will to continue to investigate hospitals and health systems that fail to comply with the ICD implantation rules.

Medtronic plc (NYSE: MDT) adds to the robust data for its IN.PACT® Admiral® drug-coated balloon (DCB)  with the presentation of both its formal cost-effectiveness analysis from the U.S. cohort of the IN.PACT SFA Trial and clinical results from the in-stent restenosis cohort data from Medtronic's IN.PACT Global Study. 

Medtronic plc (NYSE: MDT) today announced new clinical data in interventional treatments for aortic and peripheral vascular diseases in a late-breaking trial session at Vascular Interventional Advances (VIVA) 2015.

Three major cardiology societies released a new guideline on Sept. 23 to manage adults with all types of supraventricular tachycardia (SVT) other than atrial fibrillation.

The Heart Rhythm Society focused on the latest developments in electrophysiology and the management of patients with rhythm disorders and heart failure at its 2015 meeting on May 13-16 in Boston. The event included 12 late-breaking clinical trials.

While amyloid imaging is typically discussed with regard to diagnosing Alzheimer’s disease, a team of French researchers, presenting at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2015 annual meeting, have found that amyloid scans of the heart can predict major cardiac events.

At the American Society of Echocardiography (ASE) annual scientific sessions, the use of point-of-care echocardiography is among the major topics of discussion. The conference takes place from June 12 to June 16 at the Hynes Convention Center in Boston.

Thoratec Corporation, a world leader in mechanical circulatory support therapies to save, support and restore failing hearts, announced that the FDA has granted conditional approval for a U.S. IDE clinical trial to investigate use of the HeartMate PHP acute catheter-based heart pump in patients undergoing a high-risk percutaneous coronary intervention.